SEC Comment Letter for Aptose Biosciences Inc. (CIK 0000882361) (APTOF) — Feb 19, 2013
Aptose Biosciences Inc. (CIK 0000882361)
Date: Feb. 19, 2013 · CIK: 0000882361 · Accession: 0000000000-13-009231
AI Filing Summary & Sentiment
Letter
February 19, 2013 Via E -mail Elizabeth Williams Director of Finance Lorus Therapeutics Inc. 2 Meridian Road Toronto, Ontario M9W 4Z7 Canada
Re: Lorus Therapeutics Inc. Form 20-F Filed September 28, 2012 File No. 001 -32001
Dear Ms. Williams :
We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are res ponsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing include s the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Jennifer Riegel for
Show Raw Text
February 19, 2013 Via E -mail Elizabeth Williams Director of Finance Lorus Therapeutics Inc. 2 Meridian Road Toronto, Ontario M9W 4Z7 Canada Re: Lorus Therapeutics Inc. Form 20-F Filed September 28, 2012 File No. 001 -32001 Dear Ms. Williams : We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are res ponsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing include s the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jennifer Riegel for Jeffrey P. R iedler Assistant Director cc: Via E -mail Dan Miller Dorsey & Whitney LLP